Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 7/20 | 0.52 |
| ▸ | TYMP | P19971 | 2/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine SCHEMBL3234890 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL8540086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL7150054 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL9999805 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL3420352 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL18474938 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL6439535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL25259221 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL29040943 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL7249174 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38669 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746907-A1 | METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE | Gilead Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| US-5177064-A | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1993-01-05 | — | — | US | claimed |
| US-5159067-A | 5'-Diphosphohexose nucleoside pharmaceutical compositions | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 1992-10-27 | — | — | US | claimed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0273277-B1 | PHARMACEUTICAL COMPOSITION COMPRISING 3'-DEOXYTHYMIDIN-2'-ENE (3'-DEOXY-2',3'-DIDEHYDROTHYMIDINE) IN TREATING PATIENTS INFECTED WITH RETROVIRUS | YALE UNIVERSITY (US) | 1992-06-24 | — | — | EP | claimed |
| US-5109016-A | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1992-04-28 | — | — | US | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | claimed |
| US-4978655-A | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses | YALE UNIVERSITY (US) | 1990-12-18 | — | — | US | claimed |
| EP-0377846-A1 | Pharmaceutical mixture preparation containing nucleoside derivatives and pentosan polysulfate, and its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-07-18 | — | — | EP | claimed |